pubmed-article:12785198 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12785198 | lifeskim:mentions | umls-concept:C0032143 | lld:lifeskim |
pubmed-article:12785198 | lifeskim:mentions | umls-concept:C0042071 | lld:lifeskim |
pubmed-article:12785198 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
pubmed-article:12785198 | lifeskim:mentions | umls-concept:C0030190 | lld:lifeskim |
pubmed-article:12785198 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
pubmed-article:12785198 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:12785198 | pubmed:dateCreated | 2003-6-5 | lld:pubmed |
pubmed-article:12785198 | pubmed:abstractText | The levels of urokinase (uPA) and tissue type (tPA) plasminogen activators and their type 1 inhibitor (PAI-1) were determined by immunoassay in tumor cytosols and samples of histologically unaltered adjacent mucosa in gastric cancer patients. Gastric tumor revealed enhanced uPA and PAI-1 matched by decreased tPA in intact mucosa. The expression of uPA and PAI-1 was particularly was high at the later stages of the disease. The concentrations of uPA in tumor tissue increased with age. No significant correlation was established between levels of plasminogen activation system components, on the one hand, and histopathological grading of tumor, on the other. | lld:pubmed |
pubmed-article:12785198 | pubmed:language | rus | lld:pubmed |
pubmed-article:12785198 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12785198 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12785198 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12785198 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12785198 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12785198 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12785198 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12785198 | pubmed:issn | 0507-3758 | lld:pubmed |
pubmed-article:12785198 | pubmed:author | pubmed-author:ShcherbakovA... | lld:pubmed |
pubmed-article:12785198 | pubmed:author | pubmed-author:Kaz'minA IAI | lld:pubmed |
pubmed-article:12785198 | pubmed:author | pubmed-author:Kushlinski?N... | lld:pubmed |
pubmed-article:12785198 | pubmed:author | pubmed-author:OgnerubovN... | lld:pubmed |
pubmed-article:12785198 | pubmed:author | pubmed-author:GersteinE SES | lld:pubmed |
pubmed-article:12785198 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12785198 | pubmed:volume | 49 | lld:pubmed |
pubmed-article:12785198 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12785198 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12785198 | pubmed:pagination | 165-9 | lld:pubmed |
pubmed-article:12785198 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:meshHeading | pubmed-meshheading:12785198... | lld:pubmed |
pubmed-article:12785198 | pubmed:year | 2003 | lld:pubmed |
pubmed-article:12785198 | pubmed:articleTitle | [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]. | lld:pubmed |
pubmed-article:12785198 | pubmed:affiliation | N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow. | lld:pubmed |
pubmed-article:12785198 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12785198 | pubmed:publicationType | English Abstract | lld:pubmed |